Education
About Us
Working with TipRanks
Follow Us
Solid Biosciences (SLDB)
NASDAQ:SLDB
SLDB Stock Chart & Stats
$6.86
$0.18(4.59%)
At close: 4:00 PM EST
$6.86
$0.18(4.59%)
Day’s Range― - ―
52-Week Range$2.41 - $7.37
Previous CloseN/A
Volume1.97M
Average Volume (3M)1.04M
Market Cap
$507.97M
Enterprise Value$495.04M
Total Cash (Recent Filing)$236.14M
Total Debt (Recent Filing)$21.94M
Price to Earnings (P/E)―
Beta1.98
Next Earnings
Mar 18, 2026EPS Estimate
-0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding77,910,240
10 Day Avg. Volume1,097,170
30 Day Avg. Volume1,040,986
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.19
Price to Sales (P/S)0.00
P/FCF Ratio-1.62
Enterprise Value/Market Cap0.97
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-624.26
Enterprise Value/Ebitda-3.00
Forecast
1Y Price Target
$16.75Price Target Upside144.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.06
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Enrollment MomentumFull enrollment in the INSPIRE study and initiation of the randomized IMPACT Phase III study move the program toward pivotal efficacy evidence that could support regulatory submissions and strengthen commercial positioning.
Pipeline ExpansionInitiation of Phase 1b studies and early technical validation for additional programs, including dual-route administration and intradentate targeting, broadens the pipeline and creates multiple potential clinical catalysts.
Regulatory AlignmentRegulatory agency alignment on late-stage trial design and FDA agreement on using change in time-to-rise velocity as the primary endpoint improves clarity and raises the prospects for an accelerated approval pathway for SGT-003.
Bears Say
Class Safety ConcernsSafety issues with a competing gene therapy and reported deaths in non-ambulatory patients increase scrutiny of gene therapy immunosuppression strategies and could heighten regulatory and payer caution.
Information And Disclosure RiskRegulatory disclaimers, limits on redistribution, and reliance on sources presented without guarantees create information uncertainty that may constrain investor visibility and market interest.
Patient Response VariabilityVariable expression levels across patients and age-related differences in response raise the risk of inconsistent treatment outcomes in larger trials, complicating efficacy readouts and regulatory assessment.
Solid Biosciences News
SLDB FAQ
What was Solid Biosciences’s price range in the past 12 months?
Solid Biosciences lowest stock price was $2.41 and its highest was $7.37 in the past 12 months.
What is Solid Biosciences’s market cap?
Solid Biosciences’s market cap is $507.97M.
When is Solid Biosciences’s upcoming earnings report date?
Solid Biosciences’s upcoming earnings report date is Mar 18, 2026 which is in 35 days.
How were Solid Biosciences’s earnings last quarter?
Solid Biosciences released its earnings results on Nov 03, 2025. The company reported -$0.48 earnings per share for the quarter, missing the consensus estimate of -$0.439 by -$0.041.
Is Solid Biosciences overvalued?
According to Wall Street analysts Solid Biosciences’s price is currently Undervalued.
Does Solid Biosciences pay dividends?
Solid Biosciences does not currently pay dividends.
What is Solid Biosciences’s EPS estimate?
Solid Biosciences’s EPS estimate is -0.5.
How many shares outstanding does Solid Biosciences have?
Solid Biosciences has 77,910,240 shares outstanding.
What happened to Solid Biosciences’s price movement after its last earnings report?
Solid Biosciences reported an EPS of -$0.48 in its last earnings report, missing expectations of -$0.439. Following the earnings report the stock price went down -15.385%.
Which hedge fund is a major shareholder of Solid Biosciences?
Currently, no hedge funds are holding shares in SLDB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Solid Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.75 (144.17% Upside)
$16.75 (144.17% Upside)
Blogger Sentiment
Bullish
SLDB Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 73.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $822.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 11.8%
Last 30 Days ▼ 11.8%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
138.19%
12-Months-Change
Fundamentals
Return on Equity
-86.83%
Trailing 12-Months
Asset Growth
29.31%
Trailing 12-Months
Company Description
Solid Biosciences
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
SLDB Stock 12 Month Forecast
Average Price Target
$16.75
▲(144.17% Upside)